Nvp-aew541
| Title | Journal |
|---|---|
| IGF-1 prevents simvastatin-induced myotoxicity in C2C12 myotubes. | Archives of toxicology 20170501 |
| Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. | Journal of molecular endocrinology 20121001 |
| K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. | Cancer letters 20120901 |
| Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma. | Molecular cancer research : MCR 20120601 |
| Factors influencing the inhibition of protein kinases. | Journal of enzyme inhibition and medicinal chemistry 20120401 |
| Insulin-like growth factor-1 boosts the developing process of condylar hyperplasia by stimulating chondrocytes proliferation. | Osteoarthritis and cartilage 20120401 |
| Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma. | Anticancer research 20111001 |
| Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β. | Molecular cancer therapeutics 20110801 |
| Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL. | Cellular oncology (Dordrecht) 20110601 |
| Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines. | Gynecologic oncology 20110501 |
| Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. | Molecular cancer therapeutics 20110401 |
| Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. | Annals of oncology : official journal of the European Society for Medical Oncology 20110101 |
| Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. | Cancer letters 20100901 |
| Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines. | International journal of oncology 20100901 |
| Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100601 |
| Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. | World journal of gastroenterology 20100114 |
| Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL. | Analytical cellular pathology (Amsterdam) 20100101 |
| Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. | Cancer letters 20090908 |
| Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin. | Carcinogenesis 20090801 |
| Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. | Cancer research 20090515 |
| Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival. | Cancer chemotherapy and pharmacology 20090401 |
| Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. | Anti-cancer drugs 20090401 |
| Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. | Annals of oncology : official journal of the European Society for Medical Oncology 20081101 |
| Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. | Molecular cancer therapeutics 20080601 |
| The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. | British journal of haematology 20080501 |
| Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. | Journal of cellular biochemistry 20071215 |
| The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. | Leukemia 20070501 |
| Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070215 |
| Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. | World journal of gastroenterology 20060921 |
| Paradoxical effects of the phage display-derived peptide antagonist IGF-F1-1 on insulin-like growth factor-1 receptor signaling. | Biochemical pharmacology 20060628 |
| Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. | Biochemical pharmacology 20060514 |
| The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. | Endocrine-related cancer 20060301 |
| Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050801 |
| Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. | Cancer research 20050501 |
| In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. | Cancer cell 20040301 |
| Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. | Molecular endocrinology (Baltimore, Md.) |